PGI29 Quality of Life in Chronic Liver Disease

Abstract

For the overall patient sample, no statistically significant changes across visits was observed for any SIBDQ domain or total score (all PϾ0.05); mean change from baseline to endpoint did not exceed 3% for any SIBDQ score. At endpoint, patients exhibiting recurrent UC (nϭ29) scored significantly lower than non-recurrent patients (nϭ117) on bowel symptoms, emotional function, and social function domains and total score (PϽ0.001 for all differences). CONCLUSIONS: Patients with quiescent UC receiving daily treatment with MMX mesalamine (2.4 g/day) exhibited high stability, and thus strong maintenance, in disease-specific HRQoL over the course of one year. The majority of patients remained in clinical remission following one year of this treatment regimen. Patients with clinically recurrent UC showed significantly worse HRQoL outcomes than non-recurrent patients.